| Name | Title | Contact Details |
|---|
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
Infinity Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.
HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.